The abstract submission is now closed.
Publication schedule for accepted abstracts
- Abstracts accepted for presentation at ELCC 2021 as Proffered Paper, Mini Oral and E-poster will be published online on the ESMO website at 12:00hrs CET on Wednesday, 17 March 2021.
- Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.
- The publication schedule of abstracts selected for inclusion in the ELCC 2021 Press programme will be available 10 days before the Congress.
Abstracts |
Date and time |
|---|---|
|
Abstracts accepted as:
|
Wednesday, 17 March 2021, 12:00hrs CET |
Late-breaking abstracts (prefix ‘LBA’) |
At the start of the official Congress session during which they are presented. |
|
The ELCC 2021 Press programme publication schedule will be available 10 days before the Congress |
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
|
Abstract Trial in Progress Intent to submit LBA |
Tuesday, 12 January 2021, 21:00 CET (Central European Time) |
Late-breaking abstracts (LBA) |
Tuesday, 16 February 2021, 21:00 CET (Central European Time) |
Submission categories
- Tumour biology and pathology
- Translational research
- Prevention, early detection, epidemiology, tobacco control
- Imaging and staging
- SCLC
- Early stage NSCLC
- Locally advanced NSCLC
- Advanced NSCLC
- Metastases to and from the lung
- Mesothelioma
- General interest
Late-breaking abstracts (LBA)
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 12 January 2021 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ELCC 2021.
A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on of Tuesday, 12 January 2021.
Submitters of preliminary versions receiving approval to proceed must submit the final LBA by Tuesday, 16 February 2021.
Trial in progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2021
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:
- Background
- Trial design
Notes:
- Recruitment must have already begun or have been completed by the abstract submission deadline of 12 January 2021.
- Abstracts including results or preliminary data will be rejected.
- Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
- Encore TiP abstracts will NOT be accepted.
Presentation options for accepted abstracts
The ELCC 2021 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short presentation by authors with comment and interactive audience discussion led by an invited expert.
- E-poster – Display session for presentation, review, and questions.
All accepted abstracts will be published in the ELCC 2021 Abstract book, as a supplement of the official IASLC journal, Journal of Thoracic Oncology.
Travel Grants
A restricted number of travel grants are available, upon application, to first authors under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by ELCC 2021 Scientific Committee on a competitive basis from among the accepted abstracts.
More information can be found in the Abstract regulations.